Swami Subramaniam

[Swami Subramaniam @swami2m]

@airindia Great cabin, attentive service, ontime...what more can we ask for!

[Swami Subramaniam @swami2m]

Flew @airindia from BLR to Mumbai. Lovely terminal, helpful onground and onboard staff, hot meal. #AIFans #FlyAI

[IGNITE LIFE SCIENCE FOUNDATION @ignitelsf]

WELCOME TO THE 4th MEETING IN THE SERIES OF RNA SpARC WEBINARS

The mRNA Revolution: Key Patents and Legal Landscapes

14 December 2024 | 4:00 PM - 5:00 PM IST

https://t.co/fRyBUZDONM

@iiscbangalore @NCBS_Bangalore @swami2m

[Sumanth Raman @sumanthraman]

The pace of progress of AI in healthcare is mind boggling. The health sector is going to see a massive disruption within the next few years. For starters, the EMR as we know it today will be history, replaced by an AI medical record.
Patients are going to be a lot more empowered than they are now. And a part of the decision making, especially in primary care, radiology, dermatology and some other specialties is going to be machine led.
In India, the Medical community will fight tooth and nail and resist any introduction of AI into decision making, but change is coming and it is coming fast. They can adapt or be left behind in 5 years. Mark this post. #Healthcare #AI #AIinHealthcare #MEDTwitter

[Swami Subramaniam @swami2m]

@sanjeevsanyal Industrial R&D takes root in publicly funded academic science. Can Palo Alto happen without Stanford. Can Cambridge MA innovate without Harvard. The parlous state of Indian academic science must be fixed for private companies to access inventions - the lifeblood of innovation!

[Swami Subramaniam @swami2m]

150% customs duty on lab chemicals. Who are we kidding about our commitment to innovation!

[Swami Subramaniam @swami2m]

Why does healthcare not take to tech?

https://t.co/83HS52MYnP

[IGNITE LIFE SCIENCE FOUNDATION @ignitelsf]

CALL FOR PROPOSALS

ACORN-AMR FAST GRANTS 2023 (Round 2)
for breakthrough solutions for antimicrobial resistance (AMR).

Check this link for more details :
https://t.co/QAEknkyE4F

Email: [email protected].

[Ind J Med Ethics @IndJMedEthics]

In a comment published in IJME, @aranic et al propose that the N-of-1 trial be used as a practical method to evaluate Ayurvedic treatments.
https://t.co/0tRtKhjO9u

@swami2m
@amarjesani @sandhya19910 @HEaLInsti_FMES @VJ_PublicHealth @RamanathanMala

[Swami Subramaniam @swami2m]

The N of 1 trial design can help validate traditional medicines. This will be good for patients and for traditional medicine.

https://t.co/9kK7QRnkYS

[Aakar Patel @Aakar__Patel]

tru dat

[IGNITE LIFE SCIENCE FOUNDATION @ignitelsf]

@IndiaBioscience @iiscbangalore @IISERPune @tvmiiser @RamonaParsani @hurryram @swami2m

"Useful resource for anyone interested in cell and gene therapy: https://t.co/7jP8ZsPdl3".

[Swami Subramaniam @swami2m]

Ignite is keen to connect with Indian research faculty working on RNA therapeutics or vaccines. Pls DM me or send an email to [email protected] @ignitelsf @sidjhunjhunwala Please RT

[Swami Subramaniam @swami2m]

@HartoshSinghBal If he had been influenced by Gauss, Euler and Jacobi he would not have been Ramanujan. https://t.co/CsrueWmEOz

[Swami Subramaniam @swami2m]

@manoj_naandi Hello, Manoj...how can reach you direct?

[Swami Subramaniam @swami2m]

https://t.co/2ernm45o6x

[Swami Subramaniam @swami2m]

https://t.co/U2zMfgmo14

[Swami Subramaniam @swami2m]

Coming up soon!

https://t.co/U1ShiboXiB

[Swami Subramaniam @swami2m]

@DrSidMukherjee And here as well: https://t.co/gf1PNsoMF4

[Swami Subramaniam @swami2m]

Branded generic medicines: A hydra-headed problem that slams the consumer while benefiting everyone else

https://t.co/Ig3Rl0mKIC